Genezen, a cell and gene therapy Contract

Development and Manufacturing Organization (CDMO) specializing in lentiviral and

retroviral vector manufacturing, has completed another expansion phase at its viral

vector process development and cGMP vector production facility in Fishers, Indiana

(US).

In response to increased lentiviral and retroviral GMP vector demand, the latest

phase of the buildout sees additional process development, analytical development,

and quality control labs as well as GMP cell banking and GMP vector manufacturing

suites with an expanded GMP warehouse at the facility.

The latest phase of the expansion was officially opened by Indiana’s Governor Eric

Holcomb and Fishers’ Mayor Scott Fadness on September 29th, who were on site to

view the new facility with the Genezen team.

Raymond Kaczmarek, Chief Executive Officer at Genezen, commented:”We are

excited to officially open our GMP manufacturing facility in Fishers, IN. We look

forward to providing our current and future partners with high quality viral vector

material in support of their upcoming clinical trials.

“As we open this phase, we reflect on the support from our state and local

communities as well as support from our financial partners and our clients. Today’s

facility opening represents the start of the next chapter in the story of Genezen. I

am proud to see our team members embrace this opportunity to be a part of curing

the world one patient at a time.”

The continued investment into the Fishers facility allows Genezen to increase

delivery of cGMP lentiviral and retroviral vectors from adherent and suspension

processes supporting both transient transfection and producer cell line vector

manufacturing platforms. This capacity also expands Genezen’s current cGMP

capabilities for host cell expansion and host cell banking.

Bill Vincent, Founder and Executive Chairman at Genezen, commented: “With our

expansion, we’re excited to have available capacity given the high demand from

clients wanting early-stage expertise paired with scalable manufacturing process

and analytical development support, for both retro- and lentiviral vectors.

“In line with our growth strategy, planning and design are underway for our next

phase of expansion. We will continue to liaise with existing and prospective clients

to ensure we are meeting their future needs.”

The construction of the new facility was funded by a majority investment from

Ampersand Capital Partners, a private equity firm specializing in growth equity

investments in the healthcare sector.